脑膜瘤组织病理与分子检测整合的循证工作流程
研究收集1058例切除脑膜瘤的组织学信息,部分病例具备DNA甲基化、拷贝数变异、二代测序和RNA风险评分数据。整合分析发现坏死、高核分裂指数和WHO分级升高与特定分子模式相关,核分裂指数是复发最强单一预测因子,≥2个非典型组织学特征为复发预测的最佳阈值。
要点
- 核分裂指数是脑膜瘤复发最强的单一预测因子
- 存在≥2个非典型组织学特征可作为复发预测的最佳阈值
- 分子检测在低核分裂指数病例中可能具有最大附加价值
核心结论
- 部分非典型组织学特征比其他特征更具预测价值,可用于初筛以提高分子检测效率。
- 分子检测在低核分裂指数脑膜瘤中的附加价值可能最大,而非高核分裂指数病例。
研究设计与样本
- 研究纳入1058例切除脑膜瘤,收集详细组织学信息,部分病例具有基因组DNA甲基化、拷贝数变异、二代测序和RNA风险评分数据。
- 采用已知预后变量(WHO分级、Ki-67、核分裂指数及非典型组织学特征)进行整合分析。
主要发现
- 坏死、核分裂指数升高和WHO分级升高与特定DNA甲基化模式、RNA风险组和染色体拷贝数变异相关。
- 预测分析确定核分裂指数为最强的单一相关因素,并提示≥2个非典型特征为复发预测的最佳阈值。
- 片状架构是唯一独立的复发组织学相关因素。
- 高核分裂指数肿瘤无论分子谱如何均预后不良;低核分裂指数肿瘤中可识别不利分子谱的特定预测因子。
关键数值与推荐
- 复发预测的最佳阈值为存在≥2个非典型组织学特征。
- 核分裂指数为最强的单一复发预测相关因素。
- 片状架构是唯一独立的复发组织学相关因素。
临床怎么用
- 初筛时可依据非典型组织学特征(尤其是片状架构和≥2个非典型特征)决定是否进行分子检测。
- 对低核分裂指数脑膜瘤应更积极考虑分子检测以识别不利分子谱。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Meningiomas are graded using histologic and molecular criteria according to the World Health Organization (WHO) classification. However, there is scant evidence considering the specific value of each individual atypical histological feature that contributes to WHO grading. There is also little evidence-based guidance as to which cases should receive molecular testing. METHODS: Detailed histological information was collected for 1058 resected meningiomas, including cases with genomic DNA methylation and copy number variant (CNV) data, next-generation sequencing, and RNA risk score. Integrated analyses were conducted using known prognostic variables, including WHO Grade, Ki-67, mitotic index (MI), and atypical histologic features (necrosis, hypercellularity, macronucleoli, sheeting, and small cells). RESULTS: Necrosis, elevated MI, and increased WHO grade correlated with specific DNA methylation patterns, RNA risk groups, and chromosomal CNVs. Predictive analysis identified MI as the strongest single correlate, and suggested the presence of ≥ 2 atypical features as an optimal threshold for recurrence prediction. Sheeting architecture was the only independent histologic correlate of recurrence. Integration of histologic and molecular features suggests that tumors with high MI have poor prognosis regardless of molecular profile. Further analysis of low MI tumors revealed specific predictors of unfavorable molecular profiles. CONCLUSIONS: These data indicate that some atypical histopathologic features are more powerful than others, and can be used on initial screening to increase the yield of molecular profiling of meningiomas. Furthermore, we propose that molecular testing may actually have greatest added value in cases with low, not high, MI. Meningiomas are brain tumors evaluated based on features seen under the microscope and certain genetic alterations. However, it’s unclear how much each microscopic feature matters, and exactly which tumors need advanced genetic testing. In a group of over 1,000 meningiomas, tumor cell death and high numbers of dividing cells (mitotic index) were linked to more aggressive molecular patterns. The mitotic index was the single strongest predictor of recurrence. Having two or more atypical features also strongly predicted regrowth. Thus, some microscopic features are more important than others and can help decide which meningiomas should get molecular testing.
引用
- Congivaram H, Thirunavu V, Santana-Santos L, et al. An evidence-based workflow for integrating molecular testing with histopathology in the workup of meningiomas. Neuro Oncol. 2026. PMID: 42820762. doi:10.1093/neuonc/noag217
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。